Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Lymphoid Leukemia,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma,Multiple
    Sponsor: ASCO

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • DCC-2618-01-001 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Mirna Gonzalez
    RCphone 3052432441

    IRB: 20170452

    		SDG: Neurological Cancer
    Disease Site(s):

    Esophagus,Brain and Nervous System,Other Hematopoietic,Stomach,Small Intestine,Colon,Rectum,Other Digestive Organ
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    DCC-2618-01-001: A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety,Tolerability, Efficacy, and Pharmacokinetics in Patients with AdvancedMalignancies
    Eligibility Criteria - NCT02571036 *This information has been extracted from " www.clinicaltrials.gov"

  • 2102-ONC-102 - De La Fuente, Macarena

  • Investigator:
    Macarena De La Fuente
    RCname Email

    		Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone 3052438173

    IRB: 20180721

    		SDG: Neurological Cancer
    Disease Site(s):

    Brain and Nervous System,Pancreas,Bones and Joints,Soft Tissue
    Sponsor: FORMA

    Enrolling Sites:

    Sylvester
    Title:

    2102-ONC-102: A Phase 1b/2 Study of FT-2102 in Patients with Advanced Solid Tumors and Gliomas with an IDH1 Mutation
    Eligibility Criteria - NCT03684811 *This information has been extracted from " www.clinicaltrials.gov"

  • C-610-01 - Hosein, Peter

  • Investigator:
    Peter Hosein
    RCname Email

    		Coordinator:
    RCemailImg Alexander Diaz
    RCphone 3052436855

    IRB: 20180763

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Breast,Bladder,Rectum,Soft Tissue,Melanoma, skin
    Sponsor: Agenus

    Enrolling Sites:

    Sylvester
    Title:

    C-610-01:A Phase 1a First-in-Human Study of Safety and Tolerability of ASV? AGEN2017 With QS-21 Stimulon® Adjuvant as a Single Agent in Subjects with Solid Tumor at Risk of Relapse Undergoing Observation as Standard of Care Following Complete Surgical Resection
    Eligibility Criteria - NCT03673020 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191076 - Hosein Peter

  • Investigator:
    Peter Hosein
    RCname Email

    		Coordinator:

    IRB: 20191076

    		SDG: Pancreatic, Liver, and Related Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Esophagus,Breast,Prostate,Bladder,Kidney,Other Urinary,Thyroid,Non-Hodgkin Lymphoma,Hodgkin Lymphoma,Stomach,Small Intestine,Colon,Rectum,Anus,Liver,Pancreas,Other Digestive Organ,Soft Tissue,Melanoma, skin
    Sponsor: EISAI

    Enrolling Sites:

    Sylvester
    Title:

    An Open-Label, Multicenter Phase 1/1b Study of Intratumorally Administered STING Agonist E7766 in Subjects With Advanced Solid Tumors or Lymphomas ? INSTAL-101
    Eligibility Criteria - NCT04144140 *This information has been extracted from " www.clinicaltrials.gov"

  • AGEN2034 - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    		Coordinator:
    RCemailImg Harshita Gahankari
    RCphone 3052430959

    IRB: 20170076

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Cervix Uteri
    Sponsor: Agenus

    Enrolling Sites:

    Sylvester
    Title:

    C-700-01: A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer
    Eligibility Criteria - NCT03104699 *This information has been extracted from " www.clinicaltrials.gov"

  • VYR-VSV2-101 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20170023

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Lung,Melanoma, skin,Kaposis sarcoma
    Sponsor: VYRIAD

    Enrolling Sites:

    Sylvester
    Title:

    Phase I Trial of Intratumoral Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and human interferon beta (VSV-IFNß-NIS), in Patients with Refractory Solid Tumors
    Eligibility Criteria - NCT02923466 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Rakhi Modak
    RCphone 3052437387

    IRB: 20180279

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Cervix Uteri,Corpus Uteri,Prostate,Bladder,Kidney,Non-Hodgkin Lymphoma,Lymphoid Leukemia,Colon,Rectum,Pancreas,Lung,Bones and Joints,Soft Tissue
    Sponsor: CP

    Enrolling Sites:

    Sylvester
    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Colon,Breast-Female,Melanoma, skin
    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester
    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • C-500-01 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    		Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20160238

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Brain and Nervous System,Leukemia, Other,Bones and Joints,Melanoma, skin
    Sponsor: Agenus

    Enrolling Sites:

    Sylvester
    Title:

    C-500-01
    Eligibility Criteria - NCT02694822 *This information has been extracted from " www.clinicaltrials.gov"

  • AST-008-102 - Perez, Cesar

  • Investigator:
    Cesar Perez
    RCname Email

    		Coordinator:
    RCemailImg Chinar Singh
    RCphone 3052438237

    IRB: 20180957

    		SDG: Head and Neck Cancer
    Disease Site(s):

    Lip, Oral Cavity and Pharynx,Bones and Joints,Melanoma, skin
    Sponsor: EXICURE INC

    Enrolling Sites:

    Sylvester
    Title:

    AST-008-102 :A Phase 1b/2 Study of AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors
    Eligibility Criteria - NCT03684785 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC- 096 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:
    RCemailImg Sarah Lam
    RCphone 3052437586

    IRB: 20180804

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Kaposis sarcoma
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    AMC-096: A Phase II Study of sEphB4-HSA in Kaposi Sarcoma
    Eligibility Criteria - NCT02799485 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC 098 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:
    RCemailImg Sarah Lam
    RCphone 3052437586

    IRB: 20180856

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Kaposis sarcoma
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    AMC-098:A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma
    Eligibility Criteria - NCT03077451 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Slomovitz, Brian

  • Investigator:
    Brian Slomovitz
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone 3052431481

    IRB: 20150671

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Corpus Uteri,Ovary,Other Female Genital,Prostate,Kidney,Non-Hodgkin Lymphoma,Multiple Myeloma,Colon,Liver,Pancreas,Larynx,Soft Tissue,Kaposis sarcoma
    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Therapy Choice (MATCH)
    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • Anlotinib AL3818-US-004A - Trent, Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:
    RCemailImg Mirna Gonzalez
    RCphone 3052432441

    IRB: 20170072

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Soft Tissue
    Sponsor: ADVENCHEN LABORATORIES

    Enrolling Sites:

    Sylvester
    Title:

    AL3818-US-004A: Phase III Study of AL3818 (Anlotinib) HydrochlorideMonotherapy in Subjects with Metastatic or AdvancedAlveolar Soft Part Sarcoma, Leiomyosarcoma and SynovialSarcoma
    Eligibility Criteria - NCT03016819 *This information has been extracted from " www.clinicaltrials.gov"

  • DCC-2618-03-002 - Trent, Jonathan

  • Investigator:
    Jonathan Trent
    RCname Email

    		Coordinator:
    RCemailImg Mirna Gonzalez
    RCphone 3052432441

    IRB: 20181085

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Stomach
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    DCC-2618-03-002:A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumors after Treatment with Imatinib
    Eligibility Criteria - NCT03673501 *This information has been extracted from " www.clinicaltrials.gov"